welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
New Drug for Duchenne Muscular Dystrophy Clears Phase 1 Clinical Trial Testing in BoysPatients with Duchenne muscular dystroph...
-
Improvement of Duchenne Muscular Dystrophy Phenotype Following Obestatin TreatmentBackground: This study was performed to...
-
Eteplirsen is Granted Accelerated Approval in UShttps://www.youtube.com/watch?v=Orig6mpu...
-
The Effect of Kinesiology Taping on Balance in Duchenne Muscular DystrophyInvestigators investigated that the effe...
-
Ataluren treatment of patients with nonsense mutation dystrophinopathyIntroduction: Dystrophinopathy is a ra...
-
Use of Dynamic Arm Supports to Promote Activities of Daily Living in Individuals With DMDThis study is a longitudinal, randomized...
-
Long-Term Treatment With Eteplirsen in Nonambulatory Patients With Duchenne Muscular DystrophyThis analysis aims to describe the outco...
